EpiHeart

EpiHeart is a Finland-based medical device startup founded in 2019. The company's slogan, "Enabling new cardiac treatments," encapsulates its mission to facilitate the surgical administration of novel cellular and gene therapies. With a primary focus on cardiac cellular therapy administered during CABG or LVAD surgery, EpiHeart aims to address ischemic cardiac scars and heart failure. The startup operates within the Health Care and Manufacturing industries. As of the latest available data, there is no public information regarding last investment and last investment investors. EpiHeart's commitment to advancing cardiac treatments through innovative medical devices presents an intriguing opportunity for venture capitalists seeking to enter the health and biotech sectors. The company's forward-looking approach to addressing critical medical needs aligns with the growing demand for technological advancements in healthcare. EpiHeart's innovative focus and strategic location in Finland, known for its strong foundation in healthcare and technology, position it as a promising prospect for potential investors seeking to contribute to the evolution of cardiac therapies.